Search Bar & Filters
Found 15 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating whether less frequent dosing of pembrolizumab after six months of standard treatment is safe and effective for patients with advanced non-small cell lung cancer NSCLC. Pembrolizumab, an immunotherapy targeting the PD-1 receptor, has improved outcomes in NSCLC, but current dosing every six weeks for up to two years may result in overtreatment. This UK phase III trial aims to find if reducing dose frequency can maintain effectiveness while improving quality of life and lowering costs. Participants who have received six months of pembrolizumab, with or without chemotherapy, and plan to continue treatment will be randomized to receive pembrolizumab intravenously every six weeks control or every twelve weeks initially. If the 12-week dosing is found to be not less effective, additional groups receiving doses every nine, fifteen, and eighteen weeks will be included. Patients who experience disease progression while on reduced frequency dosing can return to the standard six-week schedule. Throughout the study, participants will be monitored for overall survival at 18 months from randomization, along with other outcomes such as progression-free survival, response rate, duration of response, and adverse events over two years. The study involves regular hospital visits for treatment and assessments, and the results may lead to safer, more convenient treatment options for NSCLC patients. The total participation time varies depending on individual treatment and follow-up schedules.
Actively Recruiting
Researchers are studying Raludotatug Deruxtecan R-DXd, an antibody-drug conjugate that targets CDH6 protein, in people with platinum-resistant, high-grade ovarian, primary peritoneal, or fallopian tube cancer. This trial includes a Phase 2 dose-optimization part to find the best dose based on safety and effectiveness, followed by a Phase 3 part comparing R-DXd to chemotherapy chosen by the investigator. Participants will receive R-DXd through an intravenous infusion every three weeks at varying doses during Phase 2. In Phase 3, participants will be randomly assigned to receive either R-DXd at the recommended dose or one of the chemotherapy options paclitaxel, pegylated liposomal doxorubicin PLD, or topotecan, also given intravenously every three weeks. During the study, participants will undergo scans and biopsies to evaluate tumor response and drug effects. Researchers will monitor safety, side effects, and various measures such as progression-free survival and overall survival for up to 40 months. Participants will have regular visits for treatment, assessments, and laboratory tests to track their health and response to the study treatments.
Actively Recruiting
Researchers are evaluating two types of stereotactic body radiotherapy SBRT in men with high risk localized prostate cancer, where the cancer is confined to the prostate but may grow quickly or spread. The study aims to compare the safety and effectiveness of delivering radiotherapy to the prostate alone versus the prostate plus surrounding lymph nodes, with both treatments given in only 5 sessions. This phase III trial is designed to see if including lymph nodes reduces the chance of cancer returning and to review any side effects that occur. Participants will be randomly assigned to one of two groups. One group will receive SBRT targeting the prostate and seminal vesicles, delivering 36.25Gy in 5 fractions on alternate days with 40Gy to the prostate clinical target volume. The other group will get the same prostate treatment plus 25Gy in 5 fractions to the pelvic lymph nodes on alternate days. Treatments will be provided over approximately two weeks at experienced NHS radiotherapy centers that meet quality standards for these therapies. During the study, participants will be monitored for at least three and a half years to assess time to biochemical or clinical failure, which is the main outcome. Researchers will also track acute and late side effects, cancer relapse, survival rates, patient-reported outcomes, and adherence to treatment protocols for up to five years post-randomization. Regular imaging and assessments will be performed before treatment to confirm eligibility and exclude metastatic disease. Overall, participants can expect close monitoring and follow-up throughout and after their treatment period.
Actively Recruiting
Researchers are conducting a multi-centre observational study to better understand giant cell arteritis GCA and polymyalgia rheumatica PMR, conditions mainly affecting people over 50 years old. The study aims to identify genetic factors that influence susceptibility to these diseases to provide new insights into how they develop. It includes both retrospective participants with confirmed diagnoses and prospective participants suspected of having these conditions, with some patients also enrolled in a registry monitoring tocilizumab treatment for relapsing or refractory GCA. The study collects detailed clinical, imaging, and molecular data, including genetic and proteomic analyses, from participants to characterize disease subtypes and impacts. Researchers also assess quality of life through patient-reported outcomes and track long-term prognosis by linking to health records. The study explores environmental factors and co-existing conditions to improve diagnosis, prognosis, and monitoring of disease activity, especially for patients receiving synthetic or biological disease-modifying anti-rheumatic drugs. Participants provide information during baseline assessments, including blood and urine samples for analysis, and complete questionnaires about their symptoms and quality of life. Follow-up occurs through health record review over an average of one year to evaluate diagnosis and disease outcomes. The primary measure is genetic susceptibility, with secondary outcomes focusing on disease characteristics, life impact, diagnosis, and disease activity. The study is sponsored by the University of Leeds and started in 2005, continuing through 2028.
Actively Recruiting
Healthy Volunteer
Researchers are conducting Enroll-HD, a large, ongoing observational study that combines and expands previous Huntingtons disease HD registries across multiple continents, including Europe, North America, Australasia, and Latin America. This study collects longitudinal clinical data and biological samples from individuals with manifest HD, those carrying or at risk of carrying the HD gene mutation, and control participants without the mutation. The goal is to build a rich database to support research into disease progression, prognosis, and developing clinical trial endpoints. Participants include those with diagnosed HD, pre-manifest carriers, relatives with unknown or negative genotype status, family controls, and community controls. The study involves annual assessments with no planned end date, allowing for long-term data collection. Researchers collect demographic, clinical, family history, genetic, and blood sample information systematically from over 150 sites worldwide. During the study, participants undergo motor, functional, behavioral, and cognitive assessments using standardized tools such as the Unified Huntingtons Disease Rating Scale and Problem Behaviors Assessment-Short. Data are updated at each visit, including clinical signs and genotyping results. The study database is periodically made available to researchers globally, and participants may contribute for many years, helping to advance understanding and support future interventional studies in HD.
Actively Recruiting
Researchers are evaluating surgical options for patients with low risk differentiated thyroid cancer. This phase III study aims to determine if hemithyroidectomy, which removes part of the thyroid gland, is an acceptable and cost-effective alternative to total thyroidectomy, which removes the entire gland. The trial includes two groups of patients based on their prior surgery status and diagnosis method, focusing on recurrence risk and prognosis. Participants are randomly assigned to different surgical treatments depending on their group. Group 1 patients who have had prior thyroid surgery will either have a second operation to remove the remaining thyroid tissue or undergo surveillance without further surgery. Group 2 patients who have not had surgery will be randomized to receive either hemithyroidectomy or total thyroidectomy in a single operation. The trial plans to recruit 456 participants and follow them regularly for six years after surgery. During the study, patients will attend follow-up visits post-surgery and then annually for six years. Researchers will monitor cancer recurrence rates at three and five years, assess the site and risk of recurrence, and record additional investigations and procedures after surgery. They will also evaluate surgical complications, voice function, hormone replacement needs, quality of life, and healthcare resource use at multiple time points. This comprehensive monitoring aims to compare outcomes between the different surgical approaches and understand their impact on patients health and well-being over time.
Actively Recruiting
Major depressive disorder MDD is a common and challenging condition often treated with antidepressants and talking therapies, but many people remain unwell despite these options. This research evaluates whether home-based transcranial direct current stimulation tDCS, a non-invasive brain stimulation technique, can be an effective treatment for adults with MDD when added to their usual care. The study is a multi-centre, randomized controlled trial assessing both clinical and cost-effectiveness of home-based tDCS combined with standard care compared to standard care alone. Participants are randomly assigned to either continue their usual treatment, such as psychotherapy or antidepressant medication, or to receive active tDCS at home in addition to usual care. The tDCS treatment involves using a headset with electrodes placed on specific brain regions for 36 sessions over 10 weeks, with 5 sessions per week during the first 3 weeks and 3 sessions per week for the following 7 weeks. Stimulation lasts 30 minutes per session with a gradual ramp-up and ramp-down. During the study, participants will be assessed regularly using depression rating scales like the Montgomery-sberg Depression Rating Scale MADRS at 10 weeks and 6 months to measure changes in depressive symptoms. After the 6-month follow-up, all participants can choose to start or continue tDCS treatment for an additional 3 months. The study includes safety monitoring, quality of life assessments, and evaluation of treatment acceptability, with the total follow-up lasting 9 months from the treatment start.
Actively Recruiting
Researchers are evaluating the use of two types of MRI scans and two biopsy methods to improve prostate cancer diagnosis. The study focuses on whether biparametric MRI bpMRI, which is shorter and does not use contrast dye, can be an alternative to the longer multiparametric MRI mpMRI that uses gadolinium contrast. It also compares image-fusion targeted biopsy, which overlays MRI and ultrasound images during biopsy, with visual-registration targeted biopsy, where biopsy locations are chosen by looking at MRI images separately. Participants first receive either the mpMRI or bpMRI scan. If the MRI suggests cancer, the clinical team decides if a biopsy is needed. Those advised for biopsy undergo either a visual-registration targeted biopsy or an image-fusion targeted biopsy. Both biopsy methods include taking systematic tissue samples to check for cancer. The study does not blind participants or doctors to the MRI or biopsy type used. During the study, participants undergo MRI scans and possibly biopsies based on clinical advice. Researchers collect data on how many clinically significant prostate cancers are detected within 12 weeks of enrollment. They also assess any adverse events related to MRI and biopsy procedures, patient-reported outcomes, and accuracy of cancer detection using different scoring systems. The total duration for outcome assessment is up to 12 weeks after joining the study.
Actively Recruiting
Researchers are conducting a phase III, randomized, open-label, international trial to compare ruxolitinib with the best available therapy, which includes either hydroxycarbamide or interferon alpha, as first-line treatment for patients with high-risk polycythemia vera. This trial aims to assess the effectiveness and safety of these treatments in managing the disease and preventing major complications such as thrombosis and transformation to other blood disorders. Participants will be randomly assigned to receive either ruxolitinib at a dose of 10 mg twice daily or best available therapy consisting of hydroxycarbamide or any formulation of interferon alpha chosen by the investigator before randomization. The study prohibits crossover between treatment arms during the trial period. Treatment and monitoring will continue for approximately 3 years, with assessments of blood markers, symptom burden, quality of life, and adverse events. During the trial, participants will have regular visits for monitoring their health, including blood tests for JAK2 V617F allele burden, quality of life questionnaires at several time points, and evaluation of clinical events such as thrombosis, haemorrhage, and disease progression. The primary outcome measured is event-free survival, defined by the time until major complications or death within the trial duration. Safety, symptom changes, and other secondary outcomes will be assessed continuously throughout the study, which is planned to complete by 2030.
Actively Recruiting
Researchers are evaluating the long-term reliability and performance of cardiac rhythm products marketed by Medtronic. This observational study focuses on devices such as leads, implantable pulse generators, implantable cardioverter defibrillators, and cardiac resynchronization therapy devices used for conditions like arrhythmia, bradycardia, heart failure, and sinus tachycardia. The study aims to analyze product survival probabilities and monitor lead-related complications over time. Participants include individuals who have received or will receive Medtronic market-released cardiac devices for pacing, sensing, or defibrillation. The study includes products implanted as part of routine care or participants from prior qualifying studies. Data is collected from the time of implantation and continues until the device is removed from service, the patient exits the study, or passes away. Enrollment criteria also require consent for access to health information. During the study, participants device performance is monitored through follow-up data collection. Researchers assess complications related to the implanted leads and track device status over long periods, potentially spanning several years. The study does not involve additional treatments but relies on routine clinical follow-up and health information review. The total duration extends up to December 2040, allowing comprehensive long-term evaluation of device performance.
1-10 of 15
1